AAPL 186.61 +0.12 (+0.06%)MSFT 126.9 +0.03 (+0.02%)FB 184.76 +0.03 (+0.02%)ZNGA 6.17 0 (+0.08%)NVDA 155.05 -0.2 (-0.13%)WBA 52.73 +0.06 (+0.11%)GOOG 1148.79 -1.09 (-0.09%)PIH 5.7 -0.12 (-2.06%)
AAPL 186.61 +0.12 (+0.06%)MSFT 126.9 +0.03 (+0.02%)FB 184.76 +0.03 (+0.02%)ZNGA 6.17 0 (+0.08%)NVDA 155.05 -0.2 (-0.13%)WBA 52.73 +0.06 (+0.11%)GOOG 1148.79 -1.09 (-0.09%)PIH 5.7 -0.12 (-2.06%)

Financial Summary ABLX Quote Ablynx NV

Ablynx NV Quote

Ablynx NV (ABLX)

52.78 -0.02 Healthcare
Stock Performance rating :
Recommendation :
Strong Sell
Score :
C+
Symbol ABLX
Price 52.78
Beta 8.24
Vol Avg 132.10 K
Mkt cap 4.12 B
Shares 54
Last Div Not Available
Div Yield 0.00%
DCF Unlevered 0.00
DCF Levered 0.00
ROE -392.86% Strong Sell
ROA -41.51% Strong Sell
Operating Margin -22.08% Sell
Debt/Equity 846.43% Strong Buy
P/E -51.82 Strong Sell
P/B 101.79 Strong Buy
All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Income Statement
Year 20142015201620172018
Revenue 33 48 77 0 0
COGS 44 54 83 100 91
GrossProfit -11 -7 -6 -16 -35
Depreciation (included in COGS) 2 2 1 0 0
StockBasedCompe (included in COGS) 1 2 2 3 3
ResearchAndDeve 0 0 0 0 0
SalesGeneralAnd 8 9 9 11 16
OperatingIncome -18 -16 -17 -29 -54
InterestExpense 0 0 4 7 7
OtherIncome -2 4 -34 35 -47
IncomeBeforeTax -19 -13 -55 -1 -109
ProvisionForInc 0 0 0 0 0
NetIncome -19 -13 -55 -1 -109
Balance Sheet
Year 20142015201620172018
CashAndCashEqui 11 12 4 53 15
ShortTermInvest 188 193 231 180 288
Cash 198 204 235 0 0
AccountReceivab 0 0 7 0 0
Inventories 0 0 0 0 0
DeferredIncomeT 0 0 0 0 0
OtherCurrentAss 2 3 5 5 6
TotalCurrentAss 200 207 246 242 311
PPE 19 16 18 21 23
AccumulatedDepr -17 -14 -15 -17 -19
NetPPE 2 2 3 4 4
EquityAndOtherI 0 0 0 0 50
Goodwill 0 0 0 0 0
IntangibleAsset 0 0 0 2 1
OtherLTAssets 10 14 16 19 24
TotalNonCurrent 13 17 19 25 79
TotalAssets 214 223 265 267 390
ShortTermDebt 0 0 0 0 0
AccountsPayable 5 3 4 0 0
TaxesPayable 0 0 0 0 0
AccruedLiabilit 10 11 12 0 0
DeferredRevenue 152 132 86 34 22
OtherCurrentLia 0 1 1 1 7
TotalCurrentLia 167 148 103 59 44
Debt 0 0 135 0 0
DeferredTaxesLi 0 0 0 0 0
DeferredRevenue 0 0 0 0 11
OtherLTLiabilit 0 0 0 0 66
TotalNonCurrent 0 0 135 104 166
TotalLiabilitie 167 148 237 164 210
CommonStock 84 92 96 106 118
AdditionalPaidI 151 184 187 252 425
RetainedEarning -195 -208 -262 -263 -372
AccumulatedOthe 0 0 0 0 0
TotalStockholde 46 75 28 103 180
TotalLiabilitie 214 223 265 267 390
Cash Flow Statement
Year 20142015201620172018
NetIncome -19 -13 -55 -1 -109
Depreciation 2 2 1 0 0
DeferredIncomeT 0 0 0 0 0
StockBasedCompe 1 2 2 3 3
AccountsReceiva -2 -4 -12 0 -4
InventoryCS 0 0 0 0 0
AccountsPayable 125 -19 -45 -43 -5
OtherWorkingCap 0 0 0 0 0
OtherNonCashIte 0 0 39 -27 54
NetCashProvided 106 -32 -69 -67 -58
InvestmentsInPP -1 -1 -1 -3 -2
AcquisitionsNet 0 0 0 0 0
PurchasesOfInve -131 -5 -38 0 -288
SalesMaturities 0 0 0 51 130
PurchasesOfInta 0 0 0 -2 0
OtherInvestingA 0 0 0 0 0
NetCashUsedForI -132 -6 -40 46 -160
DebtIssued 0 0 97 0 0
DebtRepayment -1 -1 0 0 0
CommonStockIssu 0 40 0 71 179
CommonStockRepu 0 0 0 0 0
DividendPaid 0 0 0 0 0
OtherFinancingA 33 1 4 -1 0
NetCashProvided 32 40 101 70 179
NetChangeInCash 6 1 -8 50 -38
CashAtBeginning 4 11 12 4 53
CashAtEndOfPeri 11 12 4 53 15
Retained Earnings
Year 20142015201620172018
RetainedEarning ----195-208
NetIncome ---19-13-55
StockDividend --21426109
DividendPaid -----
RetainedEarning ---195-208-262
Property Plant and Equipment Schedule
Year 20142015201620172018
NetPPE ---22
DeprAnnual 0--173-1
CapitalExpendit 00122
NetPPE --223
Intangible and Goodwill Schedule
Year 20142015201620172018
intAndGW 0----
Amortization 0-15-5-
NewPurchases 0--155-
intAndGW -----
Company Profile

CEO

Edwin Moses

Sector

Healthcare

Industry

Biotechnology

Exchange

Nasdaq Global Select

Description

Ablynx NV is a clinical-stage biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments.